Physician profile
Nupur Dashottar
NPI 1104844000
$1,973.98
in general payments reported to CMS, 2019-2025
16 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $262 · 2022: $181 · 2023: $376 · 2024: $513 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $862.99 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $436.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $239.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $90.93 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $62.64 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.50 | 2023 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $44.90 | 2023-2025 | Abilify Maintena, Rexulti |
| Gilead Sciences, INC. | $34.13 | 2019 | |
| Exact Sciences Corporation | $30.07 | 2025 | Cologuard Collection Kit |
| Organon LLC | $18.70 | 2025 | Nexplanon |
| Nevro Corp. | $17.94 | 2021 | |
| Amgen INC. | $17.60 | 2024 | Krystexxa |
| Currax Pharmaceuticals LLC | $16.10 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.25 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $13.88 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $12.71 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nupur Dashottar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.